Fused ring compound and use thereof
AssigneeTakeda Pharmaceutical Company Limited
InventorsTsuneo Yasuma, Nobuyuki Takakura, Yasufumi Miyamoto
Life of this patent
Estimating the term…
Abstract
The present invention provides an agent for the prophylaxis or treatment of diabetes, obesity and the like, a glucokinase activator, containing a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.
Claims21
A compound represented by the formula (I):
- wherein ring A is a 6-membered ring which is optionally further substituted;
- ring B is an optionally substituted 5- to 7-membered non-aromatic nitrogen-containing heterocycle;
- W1 is O, S, SO, SO2, an optionally substituted C1-6 alkylene group or NR4 wherein R4 is a hydrogen atom or a C1-6 alkyl group;
- R1 is an optionally substituted C6-14 aryl group or an optionally substituted heterocyclic group;
- R3 is a hydrogen atom or a halogen atom;
- (1) when W2 is O, S, SO or SO2, R2 is an optionally substituted heterocyclic group;
- and
- (2) when W2 is a bond, R2 is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-10 cycloalkyl group or an optionally substituted heterocyclic group,
- or a salt thereof.
N-M ethyl-2-{2-[5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-7-(tetrahydro-2H-pyran-4-yloxy)-1H-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl}acetamide or a salt thereof.
N-Methyl-2-[2-(5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-1H-indol-2-yl)-4,5-dihydro-1,3-thiazol-5-yl]acetamide or a salt thereof.
N,N-Dimethyl-2-[2-(5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-1H-indol-2-yl)-4,5-dihydro-1,3-thiazol-5-yl]acetamide or a salt thereof.
N-(2-Methoxyethyl)-2-[2-(5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-1H-indol-2-yl)-4,5-dihydro-1,3-thiazol-5-yl]acetamide or a salt thereof.
2-[2-(7-Ethyl-5-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-1H-indol-2-yl)-4,5-dihydro-1,3-thiazol-5-yl]-N-methylacetamide or a salt thereof.
Dependencies are inferred from the claim text.